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Abstract
Introduction—Previously, we showed that carbohydrate restriction with calorie restriction 
slowed tumor growth in xenograft mouse prostate cancer models. Herein, we examined the impact 
of carbohydrate restriction without calorie restriction on tumor development within the context of 
diet-induced obesity in the Hi-Myc transgenic mouse model of prostate cancer.
Methods—Mice were randomized at 5 weeks of age to ad libitum Western diet (WD; 40% fat, 
42% carbohydrate; n=39) or ad libitum no carbohydrate ketogenic diet (NCKD; 82% fat, 1% 
carbohydrate; n=44). At age 3 or 6 months, mice were sacrificed, prostates weighed and prostate 
histology, proliferation, apoptosis, and macrophage infiltration evaluated by H&E, Ki67, TUNEL 
and F4/80 staining, respectively. Body composition was assessed by DEXA, serum cytokines 
measured using multiplex, and Akt/mTOR signaling assessed by Western.
Results—Caloric intake was higher in the NCKD group, resulting in elevated body weights at 6 
months of age, relative to the WD group (45g vs. 38g; p=0.008). Despite elevated body weights, 
serum MCP-1 and IL-1α levels were lower in NCKD versus WD mice (p=0.046 and p=0.118, 
respectively), and macrophage infiltration was reduced in prostates of NCKD versus WD mice 
(p=0.028). Relative Akt phosphorylation and phospho-S6 ribosomal protein levels were reduced in 
prostates of NCKD versus WD mice. However, while mice randomized to NCKD had smaller 
prostates after adjustment for body weight at 3 and 6 months (p=0.004 and p=0.002, respectively), 
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NCKD mice had higher rates of adenocarcinoma at 6 months compared to WD mice (100% vs. 
80%, p=0.04).
Conclusions—Despite higher caloric intake and elevated body weights, carbohydrate restriction 
lowered serum MCP-1 levels, reduced prostate macrophage infiltration, reduced prostate weight, 
but failed to slow adenocarcinoma development. Together, these data suggest that although 
carbohydrate restriction within the context of obesity may reduce obesity-associated systemic 
inflammation, it is not sufficient to counteract obesity-associated tumor growth.
Keywords
carbohydrate restriction; diet-induced obesity; monocyte chemoattractant protein-1; prostate 
cancer; transgenic
Introduction
Obesity is associated with increased incidence of aggressive prostate cancer and elevated 
prostate cancer-specific mortality.1 Given the high prevalence of obesity in Western society2 
and the large number of men affected by prostate cancer,3 understanding the relationship 
between the two is of great importance. Furthermore, elucidating the role of obesity in 
prostate cancer is of particular interest, given its potentially modifiable nature.
While weight loss is challenging to achieve and thus human data are lacking,1 preclinical 
evidence suggests that obesity reversal (i.e. weight loss) via chronic and intermittent calorie 
restriction slows tumor growth in mouse models of prostate cancer via reduction of serum 
insulin and insulin-like growth factor (IGF) -1 levels and suppression of inflammation.4,5 
Previously, we demonstrated that dietary carbohydrate restriction slowed tumor growth 
relative to Western diet in xenograft mouse models of human prostate cancer via similar 
mechanisms as those demonstrated for calorie restriction.6,7 Of note, these tumor-
suppressive effects of carbohydrate restriction were observed despite higher caloric intake in 
the carbohydrate-restricted mice which was required to maintain equal body weights.6,7
A limitation of xenograft models of human cancer for studying obesity and cancer is their 
required use of immunocompromised mice, which develop a less severe diet-induced obesity 
phenotype relative to other models.6,7 In this study, we examined the impact of carbohydrate 
restriction on prostate tumor growth within the context of diet-induced obesity using the Hi-
Myc transgenic mouse model, a genetically-engineered prostate cancer model demonstrated 
to be sensitive to changes in energy balance.4 We hypothesized that ad libitum carbohydrate 
restriction would negate some of the tumor-promoting effects of obesity and slow prostate 
cancer growth.
Materials and Methods
Animal study design
Animal protocols were approved by the Duke University Institutional Animal Care and Use 
Committee. Hi-Myc breeding pairs were obtained from NIH MMRRC on an FVB/N genetic 
background and bred in-house. Diets were prepared by Research Diets Inc. (New 
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Brunswick, NJ, USA), and sterilized by irradiation. At 35 days of age, 83 male Hi-Myc mice 
were randomized based on body weight to receive a) ad libitum Western diet (WD, n=39; 40 
kcal% fat, 43 kcal% carbohydrate, 18% protein) or b) ad libitum no carbohydrate ketogenic 
diet (NCKD, n=44; 82 kcal% fat, 1 kcal% carbohydrate, 18% protein; Supplementary Table 
S1). Sample size was determined based upon prior studies of dietary interventions in mouse 
models.4,6,7 All mice were group-housed and body mass and average food consumption 
were measured biweekly for the study duration. Mice were euthanized using a lethal dose of 
ketamine/xylazine followed by bilateral thoracotomy at either 3 or 6 months of age. Blood 
was obtained via cardiac puncture immediately following euthanasia, allowed to clot at room 
temperature for 30 minutes, and centrifuged at 13,000 rpm for 90 seconds. Serum was 
collected and stored at −80°C. The entire genitourinary (GU) tract was removed intact and 
weighed. Seminal vesicles and bladder were removed, and the prostate was bisected and 
weighed. One half of the prostate was flash frozen in liquid nitrogen and stored at −80°C, 
while the other was fixed in 10% formalin for 48 hours and paraffin embedded. Percent body 
fat, lean mass, fat mass, and bone mineral content of each carcass were determined using 
dual energy X-ray absorptiometry (DXA; GE Lunar Piximus II, Madison, WI, USA), as 
described.8
Serum analyses
Serum parameters were assessed at 3 months (n=9 per dietary group) and 6 months of age 
(n=10 per dietary group) using Multiplex assays (Millipore Inc., Billerica, MA, USA) run on 
a BioRad 200 Bioplex multianalyte detection system (BioRad Inc., Hercules, CA, USA). 
These subgroups were selected to represent the mean body weight of each dietary group. 
Serum levels of interleukin (IL)-1α, IL-6, IL-12p70, granulocyte macrophage colony-
stimulating factor (GM-CSF) and monocyte chemoattractant protein (MCP)-1 were 
measured using the mouse cytokine/chemokine magnetic bead panel. Resistin, plasminogen 
activator inhibitor (PAI)-1, leptin and insulin were measured using the mouse adipokine 
magnetic bead panel, and adiponectin was measured using a singleplex magnetic bead assay. 
Serum levels of total insulin-like growth factor (IGF)-1 and IGF-1 binding protein 3 
(IGFBP3) levels were measured by ELISA (R&D systems, Minneapolis, MN, USA).
Histologic analysis
Formalin-fixed paraffin-embedded prostate tissue from each mouse was sectioned into three 
4 μm sections, each separated by 50 μm, and stained with hematoxylin and eosin (H&E) for 
histopathologic diagnosis. Tumor tissue was graded as mouse PIN (mPIN) and 
adenocarcinoma according to current guidelines by a single reader blind to treatment arm, 
guided by a board-certified pathologist (GVT).9 Subsequent serial sections were stained 
with antibodies against Ki67 (Thermo Scientific, Rockford, IL), TUNEL (ApopTag® Plus 
Peroxidase In Situ Apoptosis Kit; Millipore Inc.) and F4/80 (Abcam, Cambridge, MA) to 
assess proliferation, apoptosis and macrophage infiltration, respectively. Ki67 and TUNEL 
staining was conducted in both 3 and 6 month timepoints, whereas F4/80 staining was only 
carried out in the 6 month timepoint. Stained slides were scanned using an Aperio 
ScanScope and automated quantification of Ki67 and TUNEL expression was conducted 
blinded to dietary group using Definiens Tissue Studio® nuclear algorithm at the 
Translational Pathology Core, University of North Carolina at Chapel Hill. Manual 
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quantification of F4/80 expression was conducted by a board-certified pathologist blinded to 
dietary group at the Translational Pathology Core, Cedars-Sinai Medical Center. Scores 
ranging from 1 – 3 were assigned based on the number of cells staining positive for F4/80.
Western blot analyses
Frozen prostate tissue was homogenized in RIPA buffer (Pierce, Rockford, IL) containing 
HALT™ protease and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL) and 
protein concentration was determined by bicinchoninic acid (BCA) protein assay (Thermo 
Scientific, Rockford, IL). Samples from 8 mice per group per time point were pooled and 50 
mg of protein was electrophoretically separated on a 4–20% SDS-PAGE gel (BioRad Inc., 
Hercules, CA, USA) and transferred to a nitrocellulose membrane. These subgroups were 
selected to represent the mean body weight of each dietary group. Transfer was conducted at 
22V overnight at 4°C. After blocking with 5% milk in TBS containing 1% Tween-20 
(TBST), membranes were incubated with antibodies (all obtained from Cell Signaling 
Technology) as follows: Akt, phospho-Akt (Ser473), phospho-S6 ribosomal protein 
(Ser235/236), cyclin D1 (all at 1:2000 dilution), and mTOR, phospho-mTOR (Ser2448), 4E-
BP1, phospho-4E-BP1 (Thr37/46), GSK-3β, phospho-GSK-3β (Ser9), β-actin (all at 1:1000 
dilution). Protein bands were visualized by enhanced chemiluminescence (Thermo 
Scientific, Rockford, IL). Densitometric analysis was completed using ImageJ (Image J, 
NIH).
Statistical analysis
Our primary outcome was prostate weight per 25 g of body weight, selected a priori in order 
to examine the role of diet independent of body weight changes and to be consistent with 
prior studies examining the effect of diet on prostate cancer transgenic tumor growth.10 As a 
secondary outcome, we also examined differences in prostate weight unadjusted for body 
weight. Differences in body and organ weights, prostate weight, serum markers and prostate 
apoptotic and proliferative indexes were examined using student’s t tests, ensuring that 
variance was similar between groups being compared. Differences in macrophage 
infiltration and tumor histology were compared using a Fisher’s exact test.
Statistical analysis was carried out using GraphPad Prism version 5 (GraphPad Software, 
Inc., La Jolla, CA, USA) and STATA 13.0 (Stata, Corp., College Station, TX, USA). 
Statistical significance was two-sided with p < 0.05.
Results
Impact of carbohydrate restriction on body composition and bone density
Both dietary interventions produced a diet-induced obese phenotype, with average body 
weights increasing almost twofold over the course of the study (Figure 1). However, mice 
randomized to ad libitum NCKD consumed more calories per gram body weight, relative to 
mice randomized to ad libitum WD, resulting in higher mean body weights in the NCKD 
group at 3 and 6 months of age (Figure 1). After adjusting for body weight, there were no 
differences in liver or spleen weights between dietary groups at either 3 or 6 months (data 
not shown).
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Body composition analysis at sacrifice showed a non-significant trend towards increased fat 
mass and percent body fat in the NCKD group at 3 months of age (Supplementary Table 
S2). However, at 6 months, mice in the NCKD group had significantly higher fat mass (15.5 
g vs. 10.2 g, respectively; p=0.002) and percent body fat (41.8% vs. 32.2%, respectively; 
p=0.002), relative to mice in the WD group. There was no difference in lean body mass 
between dietary groups at either 3 or 6 months (Supplementary Table S2). While mice 
randomized to the NCKD group had significantly higher bone mineral content at 6 months 
of age (p=0.009), this association was attenuated following adjustment for body weight 
(linear regression, p=0.166).
Impact of carbohydrate restriction on prostate weight and histology
Mice consuming NCKD had significantly smaller GU tracts at both 3 months (0.30g vs. 
0.33g per 25g body weight; p=0.015) and at 6 months of age (0.34g vs. 0.41g per 25g body 
weight; p=0.018). Similarly, prostate weights were significantly lower in NCKD mice at 3 
months (0.075g vs. 0.093g per 25g body weight; p=0.004) and 6 months (0.107g vs. 0.135g 
per 25g body weight; p=0.002; Figure 2). When prostate weight was not adjusted for body 
weight, though prostate weights were smaller in NCKD mice at 3 months (0.10g vs. 0.12g, 
p=0.104) and 6 months (0.20g vs. 0.21g, p=0.501), differences were no longer statistically 
significant.
Approximately the same proportion of each dietary group had mPIN by 3 months 
(Supplementary Table S3). At 3 months of age, there were no adenocarcinomas in either 
group. However, 100% (n=23/23) of mice in the NCKD group had adenocarcinoma at 6 
months of age, compared with 80% (n=16/20) of mice in the WD group (p=0.04; 
Supplementary Table S3 and Figure S1). There were no significant differences in rates of 
proliferation or apoptosis between dietary groups at either 3 or 6 months (Supplementary 
Table S4 and Supplementary Figure S2). Results were similar when Ki67 and TUNEL 
quantification was restricted to regions of mPIN and tumor only (data not shown).
Impact of carbohydrate restriction on serum growth factors and cytokines, and prostate 
inflammation
There were no significant differences in levels of serum growth factors, cytokines or 
chemokines between dietary groups at 3 months of age (Supplementary Figure S3). At 6 
months of age, while there was a suggestion of higher IGF-1 levels in the NCKD relative to 
the WD group (p=0.073; Figure 3), there were no significant differences in serum insulin, 
IGF-1 or IGFBP3 levels between dietary groups, despite significantly larger body weights in 
the NCKD group. While adiponectin levels did not differ significantly between dietary 
groups, leptin levels were significantly elevated in the NCKD group at 6 months (p=0.024) 
and there was a non-significant trend towards increased resistin in the NCKD group 
(p=0.076). Conversely, MCP-1 levels were significantly lower in the NCKD group at 6 
months (p=0.046) and there was a suggestion of reduced levels of IL-1α (p=0.118; Figure 
3), relative to the WD group. There were no differences in levels of IL-6, PAI-1, GM-CSF or 
IL-12p70 between dietary groups (all p>0.5; Figure 3).
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Given the role of MCP-1 in regulating monocyte recruitment and activation to produce 
macrophages,11 we used F4/80 staining to identify macrophages in prostate tissue. 
Macrophage infiltration was reduced in prostates of NCKD mice, relative to their WD 
counterparts (p=0.028; Figure 4).
Impact of carbohydrate restriction on Akt/mTOR signaling
As anticipated, given their higher caloric intake, larger body weights and greater adiposity 
levels, mice randomized to NCKD had elevated prostate levels of total Akt and mTOR 
(Figure 5). However, there was a mixed picture of diet-dependent effects on Akt/mTOR 
pathway activation based on phosphorylation (p) levels (relative to total levels) of each of 
several markers, including no observed differences between the diets for pmTOR or 
pGSK-3β at 3 or 6 months of age. However, p-Akt was reduced in the NCKD group at both 
3 and 6 months. Relative phosphorylation of 4E-BP1 was higher in the NCKD group at 3 
months, but there were no differences between dietary groups at 6 months of age. Similarly, 
expression of cyclin D1 was elevated in the NCKD group at 3 months of age, but did not 
differ between dietary groups at 6 months of age. Finally, phosphorylated S6 ribosomal 
protein levels, a translational regulator downstream of mTOR, were reduced in the NCKD 
group at both 3 and 6 months.
Discussion
The association between obesity and prostate cancer is of interest for prostate cancer 
prevention efforts due to the high prevalence and potentially modifiable nature of obesity. 
Herein, we report that dietary carbohydrate restriction may offset some of the pro-
inflammatory effects of diet-induced obesity in a transgenic mouse model of prostate cancer. 
However, relative to WD, carbohydrate restriction was accompanied by higher calorie intake 
and greater weight gain and, despite lower prostate weights, carbohydrate-restricted mice 
had a higher frequency of adenocarcinoma. Together, our findings suggest that although 
carbohydrate restriction in the presence of caloric excess may offset some of the pro-
inflammatory properties of obesity, it does not slow tumor development in this model.
A randomized controlled weight loss trial in obese, cancer-free humans reported that 
carbohydrate restriction in the absence of calorie restriction promoted the most weight loss 
and had the most favorable improvement in lipid profile, relative to low fat restricted calorie 
and Mediterranean restricted calorie diets.12 However, mean weight loss in the 
carbohydrate-restricted group was relatively modest at 4.7 kg (1.5 BMI units) over the trial 
period of two years.13 Moreover, almost 90% of weight lost was regained after the trial 
period ended, even though the majority of individuals reported continuing carbohydrate 
restriction at the five year follow up.12 Interestingly, despite this modest weight loss which 
was largely regained, the favorable effects on lipid profile persisted,12 suggesting a 
beneficial role for carbohydrate restriction even in the context of obesity. In keeping with 
this observation, we demonstrate that despite 15% larger mean body weight, only serum 
leptin levels were significantly elevated in carbohydrate-restricted mice, with no significant 
increases in other obesity-associated growth factors and adipokines. Indeed, serum levels of 
the pro-inflammatory chemokine, MCP-1, were significantly reduced in carbohydrate 
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restricted mice, as was macrophage infiltration in the prostate, in spite of the significantly 
higher body weights in the carbohydrate restricted group. These findings suggests that 
carbohydrate restriction may counteract both systemic and prostate-specific pro-
inflammatory effects of obesity.
MCP-1 is an obesity-associated chemokine with a role in recruiting and activating 
monocytes during the inflammatory response and has been demonstrated to promote prostate 
tumor survival via Akt signaling.11 Several studies have suggested that MCP-1 plays a role 
in development of bone metastases14 and castrate-resistant prostate cancer.15 Previous work 
has shown that MCP-1 is an important mediator of prostate cancer growth in vivo via 
regulation of macrophage infiltration16,17 and that levels of MCP-1 and p-Akt are elevated 
following a high fat, high carbohydrate dietary intervention in a xenograft mouse model of 
prostate cancer, relative to control diet.18 While a Phase 2 trial of a monoclonal antibody 
against MCP-1 in metastatic, castrate-resistant prostate cancer patients did not result in 
sustained reduction of serum MCP-1 levels,19 there is evidence to suggest that carbohydrate 
restriction lowers serum MCP-1 levels independent of weight loss in humans,20 suggesting 
that the impact of dietary carbohydrate restriction on MCP-1 and tumor progression should 
be explored in prostate cancer patients.
Diet-induced obesity drives prostate tumor growth by increasing IGF-1 levels, activating the 
Akt/mTOR pathway and promoting pro-inflammatory signaling, while calorie restriction 
opposes these effects to slow prostate tumor growth.4 Previously, we demonstrated that 
carbohydrate restriction in the absence of calorie restriction slowed tumor growth in 
xenograft mouse models of prostate cancer via reduction of serum insulin and IGF-1 levels 
and decreased tumor Akt signaling and inflammation.7 These findings suggested that 
carbohydrate restriction without calorie restriction may mimic the chemopreventive 
properties of calorie restriction. In this current study, Akt phosphorylation and phospho-S6 
ribosomal protein levels were reduced in the tumors of carbohydrate-restricted mice, 
suggesting that carbohydrate restriction may counteract obesity-associated Akt/mTOR 
pathway signaling. However, although prostate size was reduced, carbohydrate restriction in 
the absence of calorie restriction promoted the development of prostate adenocarcinoma in 
this transgenic mouse model. Prior studies support obesity as a driver of tumor development 
in this model.4,21 Whether the failure of carbohydrate restriction to slow tumor development 
indicates that it alone is inadequate to completely counteract the tumor-promoting influence 
of obesity, or that it is unable to counteract the strong genetic driver of prostate tumor 
development in this transgenic model, is unknown. Thus, further studies are needed in 
additional transgenic mouse models of prostate cancer to better understand the interplay 
between genetics, obesity and diet with regard to prostate cancer progression.
In the current model, ad libitum carbohydrate restriction resulted in weight gain and diet-
induced obesity. Importantly, this is in contrast to human studies, wherein carbohydrate 
restriction without calorie restriction causes modest weight loss. In regards to human 
prostate cancer, we hypothesize that the beneficial effects of weight loss and carbohydrate 
restriction may work in concert to slow prostate cancer progression. Given that carbohydrate 
restriction in humans is a well-tolerated dietary intervention with favorable effects on lipid 
profile,12 and given the potential of lipid levels to alter prostate cancer growth,22 future 
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studies are required to determine whether this dietary intervention, alone or in combination 
with various prostate cancer treatments, may have a favorable impact on prostate cancer 
progression in patients.
In summary, we show that carbohydrate restriction, in the presence of caloric excess leading 
to marked obesity, opposed both systemic and prostate-specific pro-inflammatory effects of 
diet-induced obesity in the Hi-Myc transgenic mouse model of prostate cancer but was 
insufficient to counteract obesity-driven tumor development. Data from clinical trials 
suggest that carbohydrate restriction without calorie restriction may be a safe and feasible 
dietary regimen over the long-term period required for cancer prevention in humans. Given 
that carbohydrate restriction is accompanied by moderate weight loss in humans, future 
studies in prostate cancer mouse models should explore the effect of carbohydrate restriction 
in combination with weight loss on tumor growth.
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Figure 1. 
Impact of carbohydrate restriction on caloric intake (A) and body weight over the course of 
the study (B) and at 3 months (C) and 6 months of age (D). WD=Western diet, dashed line 
and empty circles; NCKD=no carbohydrate ketogenic diet, solid line and solid circles. P 
values by student’s t test.
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Figure 2. 
Impact of carbohydrate restriction on prostate size at 3 months of age (A) and 6 months of 
age (B). WD=Western diet, empty circles; NCKD=no carbohydrate ketogenic diet, solid 
circles. P values by student’s t test.
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Figure 3. 
Impact of carbohydrate restriction on serum growth factor and cytokine levels at 6 months of 
age. WD=Western diet, empty bars; NCKD=no carbohydrate ketogenic diet, solid bars. P 
values by student’s t test.
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Figure 4. 
Representative images of macrophage infiltration in tumors of mice fed a Western diet (A) 
and a no-carbohydrate ketogenic diet (B). Macrophage infiltration was significantly reduced 
in the tumors of NCKD mice relative to WD mice, as assessed by Fischer’s exact test 
(p=0.028; C).
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Figure 5. 
Impact of carbohydrate restriction on the Akt signaling pathway in the prostate. 
Densitometry shows relative phosphorylation levels of Akt, mTOR, 4E-BP1, GSK-3B and 
relative expression levels of pS6 and cyclin D1.
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